top of page
Our Team
Allievex Team
Board Of Directors
Investors
Our Focus
Tralesinidase Alfa
About Sanfilippo Syndrome Type B
Pipeline
Investors & Media
News, Events & Publications
Partner With Us
Clinicians & Access
Patients & Caregivers
More
Use tab to navigate through the menu items.
Contact Us
Investors & Media
Allievex is planning to expand its investor syndicate with Series B financing.
Email Investor Relations for more information
All Posts
Recent News
Events
Publications
Nov 2, 2022
Intracerebroventricular dosing of N-sulfoglucosamine Sulfohydrolase Inmucopolysaccharidosis Mice
Nov 2, 2022
Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations
Nov 2, 2022
Longitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIB
Mar 21, 2022
Marcus Rashford and Chris Martin join mother’s plea for son, 9, to access ‘life-saving’ trial drug
Mar 21, 2022
Boston Herald Opinion "Tom Mathers: CMS decision puts future disease cures in crosshairs"
Jan 26, 2021
WORLDSymposium™ 2021
Jan 26, 2021
Tralesinidase Alfa Pre-Clinical Publications
Jan 26, 2021
GM1 Gangliosidosis Pre-Clinical Publication
Nov 12, 2020
Sanfilippo Foundation Switzerland’s 3rd International Conference
Oct 31, 2019
Allievex to Continue BioMarin’s Clinical Program Testing Tralesinidase Alfa for Sanfilippo T
Oct 23, 2019
Allievex Completes Series A Financing Led by Pappas Capital and Novo Holdings
bottom of page
